Noema Pharma, Founded by Sofinnova Partners, Raises CHF 103 Million (USD 112 Million) in Series B Financing
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that Noema Pharma (“Noema”), has raised an oversubscribed CHF 103 million (approx. USD 112 million) Series B financing round. Sofinnova co-founded and seed financed Noema in 2019 with Dr. George Garibaldi and Luigi Costa. The company was established to advance clinical stage assets in-licensed from Roche.
Noema is a clinical-stage biopharmaceutical company focused on central nervous system disorders. Existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus welcomed new investors Forbion and Jeito Capital, as well as UPMC Enterprises and another undisclosed investor.
The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets, including its lead compound basimglurant (NOE-101), an mGluR5 inhibitor that is being evaluated in Phase 2b clinical trials for severe pain in Trigeminal Neuralgia (TN) and seizures in Tuberous Sclerosis Complex (TSC). The company is also developing gemlopodect (NOE-105), a PDE10a inhibitor being evaluated in Phase 2b clinical trials for Tourette Syndrome and Childhood Onset Fluency Disorder (COFD) or Stuttering; and NOE-115, a Phase 2 ready triple reuptake inhibitor for Atypical Depression and Binge Eating Disorder.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “As co-founders and initial investors of Noema, we are incredibly proud of what the company has accomplished since its inception. Raising an oversubscribed funding round of this magnitude is a significant achievement that further reinforces our conviction that Noema can make a meaningful difference in the lives of patients suffering from debilitating CNS disorders . Noema is the perfect illustration of our core strategy and expertise: we nurture innovative companies centered on groundbreaking science and exceptional talent that have the potential to deliver transformative results for patients.”
Luigi Costa, Chief Executive Officer of Noema Pharma, said: "We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.”
The Series B financing follows a CHF 54 million (approx. USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners. Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
About Noema Pharma
Noema Pharma (www.noemapharma.com) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the leading venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005296/en/
Contact information
Bommy Lee
Head of Communications
Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PayPay Is Now Accepted in South Korea via Ant International’s Alipay+16.9.2025 11:26:00 EEST | Press release
Starting from late September 2025, Japan's leading cashless payment service PayPay will be accepted at over 2 million merchants across South Korea through Alipay+, a global wallet gateway service operated by Ant International. This will allow its 70 million registered users to make seamless payments during their visit, wherever the Alipay+ logo is displayed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915612411/en/ Starting from late September 2025, Japanese travellers will be able to use PayPay to make payments in South Korea at stores displaying the Alipay+ logo. PayPay will show users the payment amount in Korean won and its yen equivalent in real time. This marks a new chapter in PayPay’s overseas expansion. From K-beauty stores and convenience chains to local eateries and cultural hotspots, from modern shopping malls to traditional markets, users who complete identity verification (eKYC) on PayPay app in Japan wil
Talent shortages and AI pressures drive shifting dynamics in global technology leadership, According to Expereo16.9.2025 11:00:00 EEST | Press release
Global businesses are facing mounting challenges in their growth ambitions due to persistent skills shortages in critical technology areas. As AI becomes more deeply embedded in business strategy, organisations are struggling to find or retain talent in key domains such as networking (39%), cybersecurity (40%), and Data/AI/automation (33%). The findings come from an IDC InfoBrief commissioned by Expereo, titled “Enterprise Horizons 2025: Technology Leaders Priorities: Achieving Digital Agility.” The report reveals that 39% of organisations are struggling to find or retain networking talent, while 33% report similar challenges in data, AI, and automation - figures that remain consistent with 2024 findings. These shortages are not only slowing down AI adoption but also reshaping leadership dynamics and workforce strategies across enterprises. To address these gaps, businesses are increasingly looking outward for support. 45% of global businesses expect to increase their reliance on exter
Infobip Achieves GSMA Open Gateway Certifications for Network APIs16.9.2025 11:00:00 EEST | Press release
Global communications platform Infobiphas received two new Network API certifications from the GSMA, as part of the CAMARA project. The SIM Swap and Number Verification certifications demonstrate Infobip's commitment to advancing global standards for Network APIs through the GSMA Open Gateway initiative. The certifications mark a significant milestone for Infobip and its telco partners worldwide. The certifications validate Infobip's expertise and support mobile network operators (MNOs) in achieving their own certifications as part of GSMA's global standardization efforts. Viktorija Radman, Telecom Growth & Strategy Director at Infobip, said:"Achieving GSMA certifications for SIM Swap and Number Verification demonstrates our commitment to building secure, scalable solutions for operators worldwide. As a CPaaS enabler, Infobip is dedicated to helping telcos embrace new global standards and bring the benefits of Network APIs to real-world use cases. With its experience, partnerships, and
iBASIS and XLSMART Announce Strategic Management Service Agreement to Manage International and Domestic Mobile Authentication Traffic16.9.2025 10:00:00 EEST | Press release
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and PT XLSMART Telecom Sejahtera Tbk (XLSMART), formerly known as PT XL Axiata Tbk and PT Smartfren Telecom Tbk, today announced the signing of a Management Service Agreement designed to enhance the efficiency and security of Mobile Authentication traffic delivered into the XLSMART network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916416751/en/ From left to right: Andrijanto Muljono, Director & Chief Enterprise & Strategic Relationship Officer, XLSMART; Patrick George, CEO, iBASIS This agreement is a key part of XLSMART's long-term strategy to strengthen its enterprise business and digital services. iBASIS will serve as the unique international and domestic authorized gateway for Mobile Authentication traffic into XL network prefixes. The primary benefit of this collaboration is improved security for XLSMART’s custo
Groundbreaking New Sensor Transforms How Europe Tracks Pollution, Smoke and Cloud From Space16.9.2025 10:00:00 EEST | Press release
The first images from the Multi-Viewing, Multi-Channel, Multi-Polarisation Imager, presented at the 2025 EUMETSAT Conference, reveal the brand-new instrument’s exceptional ability to monitor the Earth’s atmosphere from multiple perspectives, to support improved forecasts and air pollution and climate monitoring. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915322837/en/ 3MI’s very first image, captured between 10:59 and 11:03 CEST on 28 August 2025, confirmed the instrument is already performing well as it delivers its preliminary data streams. The left panel shows a standard view using natural light, highlighting clouds and land surfaces. The right panel, based on polarised light measurements, reveals much finer detail of the atmosphere’s composition – such as subtle cloud structures over Italy and wildfire smoke on the right edge of the image, over Greece. When sunlight interacts with particles in the air, like drople
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom